135 related articles for article (PubMed ID: 33561557)
21. Expression profiling-based subtyping identifies novel non-small cell lung cancer subgroups and implicates putative resistance to pemetrexed therapy.
Hou J; Lambers M; den Hamer B; den Bakker MA; Hoogsteden HC; Grosveld F; Hegmans J; Aerts J; Philipsen S
J Thorac Oncol; 2012 Jan; 7(1):105-14. PubMed ID: 22134068
[TBL] [Abstract][Full Text] [Related]
22. Implication of epithelial-mesenchymal transition in IGF1R-induced resistance to EGFR-TKIs in advanced non-small cell lung cancer.
Zhou J; Wang J; Zeng Y; Zhang X; Hu Q; Zheng J; Chen B; Xie B; Zhang WM
Oncotarget; 2015 Dec; 6(42):44332-45. PubMed ID: 26554308
[TBL] [Abstract][Full Text] [Related]
23. The efficacy and toxicity of maintenance therapy with bevacizumab plus pemetrexed versus bevacizumab/pemetrexed alone for stage IIIB/IV nonsquamous non-small cell lung cancer: A meta-analysis of randomized controlled trials.
Liu M; Luo N; Fang Z; Liu Q; Yi F; Wei Y; Zhang X; Zhang W
J Clin Pharm Ther; 2022 Feb; 47(2):157-167. PubMed ID: 34617297
[TBL] [Abstract][Full Text] [Related]
24. Downregulation of both EGFR and ErbB3 improves the cellular response to pemetrexed in an established pemetrexed‑resistant lung adenocarcinoma A549 cell line.
Yu Z; Li XM; Liu SH; Liu B; Gao CH; Hou X
Oncol Rep; 2014 Apr; 31(4):1818-24. PubMed ID: 24549863
[TBL] [Abstract][Full Text] [Related]
25. Significance of thymidylate synthase expression for resistance to pemetrexed in pulmonary adenocarcinoma.
Yang M; Fan WF; Pu XL; Liu FY; Meng LJ; Wang J
Oncol Lett; 2014 Jan; 7(1):227-232. PubMed ID: 24348854
[TBL] [Abstract][Full Text] [Related]
26. Arenobufagin, isolated from toad venom, inhibited epithelial-to-mesenchymal transition and suppressed migration and invasion of lung cancer cells via targeting IKKβ/NFκB signal cascade.
Zhao J; Zhang Q; Zou G; Gao G; Yue Q
J Ethnopharmacol; 2020 Mar; 250():112492. PubMed ID: 31866511
[TBL] [Abstract][Full Text] [Related]
27. Elevated SRC3 expression predicts pemetrexed resistance in lung adenocarcinoma.
Chen Y; Sun Y; Zhao W; Ma Y; Yan Z; Nie X
Biomed Pharmacother; 2020 May; 125():109958. PubMed ID: 32036219
[TBL] [Abstract][Full Text] [Related]
28. ITRAQ-Based Proteomics Analysis of Triptolide On Human A549 Lung Adenocarcinoma Cells.
Li F; Zhao D; Yang S; Wang J; Liu Q; Jin X; Wang W
Cell Physiol Biochem; 2018; 45(3):917-934. PubMed ID: 29428961
[TBL] [Abstract][Full Text] [Related]
29. Novel drug-resistance mechanisms of pemetrexed-treated non-small cell lung cancer.
Tanino R; Tsubata Y; Harashima N; Harada M; Isobe T
Oncotarget; 2018 Mar; 9(24):16807-16821. PubMed ID: 29682186
[TBL] [Abstract][Full Text] [Related]
30. Randomized phase II study of pemetrexed or pemetrexed plus bevacizumab for elderly patients with previously untreated non-squamous non-small cell lung cancer: Results of the Lung Oncology Group in Kyushu (LOGIK1201).
Fukuda M; Kitazaki T; Ogawara D; Ichiki M; Mukae H; Maruyama R; Nakagaki N; Shimada M; Ikeda T; Kishimoto J; Harada T; Seto T; Ebi N; Takayama K; Okamoto I; Ichinose Y; Sugio K
Lung Cancer; 2019 Jun; 132():1-8. PubMed ID: 31097081
[TBL] [Abstract][Full Text] [Related]
31. Reelin Promotes Cisplatin Resistance by Induction of Epithelial-Mesenchymal Transition via p38/GSK3β/Snail Signaling in Non-Small Cell Lung Cancer.
Li JM; Yang F; Li J; Yuan WQ; Wang H; Luo YQ
Med Sci Monit; 2020 Aug; 26():e925298. PubMed ID: 32764530
[TBL] [Abstract][Full Text] [Related]
32. Nitric oxide (NO) enhances pemetrexed cytotoxicity via NO‑cGMP signaling in lung adenocarcinoma cells in vitro and in vivo.
Nagai H; Yasuda H; Hatachi Y; Xue D; Sasaki T; Yamaya M; Sakamori Y; Togashi Y; Masago K; Ito I; Kim YH; Mio T; Mishima M
Int J Oncol; 2012 Jul; 41(1):24-30. PubMed ID: 22552400
[TBL] [Abstract][Full Text] [Related]
33. CD74-ROS1 G2032R mutation transcriptionally up-regulates Twist1 in non-small cell lung cancer cells leading to increased migration, invasion, and resistance to crizotinib.
Gou W; Zhou X; Liu Z; Wang L; Shen J; Xu X; Li Z; Zhai X; Zuo D; Wu Y
Cancer Lett; 2018 May; 422():19-28. PubMed ID: 29477381
[TBL] [Abstract][Full Text] [Related]
34. Dasatinib modulates sensitivity to pemetrexed in malignant pleural mesothelioma cell lines.
Monica V; Lo Iacono M; Bracco E; Busso S; Di Blasio L; Primo L; Peracino B; Papotti M; Scagliotti G
Oncotarget; 2016 Nov; 7(47):76577-76589. PubMed ID: 27391433
[TBL] [Abstract][Full Text] [Related]
35. Circular RNA hsa_circ_0096157 contributes to cisplatin resistance by proliferation, cell cycle progression, and suppressing apoptosis of non-small-cell lung carcinoma cells.
Lu H; Xie X; Wang K; Chen Q; Cai S; Liu D; Luo J; Kong J
Mol Cell Biochem; 2020 Dec; 475(1-2):63-77. PubMed ID: 32767026
[TBL] [Abstract][Full Text] [Related]
36. Clinical benefit from pemetrexed before and after crizotinib exposure and from crizotinib before and after pemetrexed exposure in patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer.
Berge EM; Lu X; Maxson D; Barón AE; Gadgeel SM; Solomon BJ; Doebele RC; Varella-Garcia M; Camidge DR
Clin Lung Cancer; 2013 Nov; 14(6):636-43. PubMed ID: 23931899
[TBL] [Abstract][Full Text] [Related]
37. Genetic determinants of pemetrexed responsiveness and nonresponsiveness in non-small cell lung cancer cells.
Wu MF; Hsiao YM; Huang CF; Huang YH; Yang WJ; Chan HW; Chang JT; Ko JL
J Thorac Oncol; 2010 Aug; 5(8):1143-51. PubMed ID: 20559153
[TBL] [Abstract][Full Text] [Related]
38. Efficacy of S-1 after pemetrexed in patients with non-small cell lung cancer: A retrospective multi-institutional analysis.
Takemoto S; Akagi K; Ono S; Tomono H; Honda N; Suyama T; Umeyama Y; Dotsu Y; Taniguchi H; Ogawara D; Senju H; Gyotoku H; Sugasaki N; Yamaguchi H; Nakatomi K; Fukuda M; Mukae H
Thorac Cancer; 2021 Sep; 12(17):2300-2306. PubMed ID: 34255933
[TBL] [Abstract][Full Text] [Related]
39. Epithelial to mesenchymal transition in an epidermal growth factor receptor-mutant lung cancer cell line with acquired resistance to erlotinib.
Suda K; Tomizawa K; Fujii M; Murakami H; Osada H; Maehara Y; Yatabe Y; Sekido Y; Mitsudomi T
J Thorac Oncol; 2011 Jul; 6(7):1152-61. PubMed ID: 21597390
[TBL] [Abstract][Full Text] [Related]
40. Blocking the epithelial-to-mesenchymal transition pathway abrogates resistance to anti-folate chemotherapy in lung cancer.
Liang SQ; Marti TM; Dorn P; Froment L; Hall SR; Berezowska S; Kocher G; Schmid RA; Peng RW
Cell Death Dis; 2015 Jul; 6(7):e1824. PubMed ID: 26181204
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]